dc.contributor.author | Puttananjaiah, M.H. | |
dc.contributor.author | Dhale, M.A. | |
dc.contributor.author | Gaonkar, V. | |
dc.contributor.author | Keni, S. | |
dc.date.accessioned | 2011-03-09T10:56:07Z | |
dc.date.available | 2011-03-09T10:56:07Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Applied Biochemistry and Biotechnology, vol.163(2); 2011; 215-222 | |
dc.identifier.uri | http://drs.nio.org/drs/handle/2264/3812 | |
dc.description.abstract | Atherosclerosis is a chronic inflammatory disease of multiple etiologies. It is associated with the accumulation of oxidized lipids in arterial lesions leading to coronary heart disease. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (commonly known as statins) are widely used in cardiovascular disease prevention to lower the cholesterol. The antioxidant activity of HMG-CoA reductase inhibitors was studied by lipid peroxidation inhibition assay, DPPH, and hydroxyl radical scavenging-activity methods. The lovastatin (93%) and simvastatin (96%) showed significant action of lipid peroxidation inhibition compared to other HMG-CoA reductase inhibitors. The DPPH radical and hydroxyl radical scavenging activity of simvastatin was 38% and 33%, respectively. The oxidative modification of serum lipid due to reactive oxygen species causes atherosclerosis. This study revealed the importance of lovastatin and simvastatin to prevent oxidative stress-related cardiovascular diseases | |
dc.language.iso | en | |
dc.publisher | Springer | |
dc.rights | An edited version of this paper was published by Springer. This paper is for R & D purpose and Copyright [2011] Springer. | |
dc.subject | Antioxidant | |
dc.subject | Lipid peroxidation | |
dc.subject | Hydroxyl radical | |
dc.subject | Atherosclerosis | |
dc.title | Statins: 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity | |
dc.type | Journal Article | |